4.7 Article

Effect of Definition on Incidence and Prognosis of Type 2 Myocardial Infarction

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 70, 期 13, 页码 1558-1568

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.07.774

关键词

diagnosis; high-sensitivity cardiac troponin; type 2 myocardial infarction

资金

  1. Swiss National Science Foundation
  2. Swiss Heart Foundation
  3. European Union
  4. Cardiovascular Research Foundation Basel
  5. University Hospital Basel
  6. Abbott
  7. Brahms
  8. Beckman Coulter
  9. Biomerieux
  10. Roche
  11. Nanosphere
  12. Siemens
  13. 8sense
  14. Buhlmann
  15. Singulex
  16. Swiss National Science Foundation [P300PB-167803/1, PASMP3-136995]
  17. Goldschmidt-Jacobson-Foundation
  18. Professor Max Cloetta Foundation
  19. Uniscientia Foundation Vaduz
  20. University of Basel
  21. Department of Internal Medicine
  22. Department of Internal Medicine, University Hospital Basel
  23. KTI
  24. Stiftung fur kardiovaskulare Forschung Basel
  25. Alere
  26. AstraZeneca
  27. Sphingotec

向作者/读者索取更多资源

BACKGROUND Uncertainties regarding the most appropriate definition and treatment of type 2 myocardial infarction (T2MI) due to supply-demand mismatch have contributed to inconsistent adoption in clinical practice. OBJECTIVES This study sought a better understanding of the effect of the definition of T2MI on its incidence, treatment, and event-related mortality, thereby addressing an important unmet clinical need. METHODS The final diagnosis was adjudicated in patients presenting with symptoms suggestive of myocardial infarction by 2 independent cardiologists by 2 methods: 1 method required the presence of coronary artery disease, a common interpretation of the 2007 universal definition (T2MI(2007)); and 1 method did not require coronary artery disease, the 2012 universal definition (T2MI(2012)). RESULTS Overall, 4,015 consecutive patients were adjudicated. The incidence of T2MI based on the T2MI(2007) definition was 2.8% (n = 112). The application of the more liberal T2MI(2012) definition resulted in an increase of T2MI incidence of 6% (n = 240), a relative increase of 114% (128 reclassified patients, defined as T2MI(2012reclassified)). Among T2MI(2007), 6.3% of patients received coronary revascularization, 22% dual-antiplatelet therapy, and 71% high-dose statin therapy versus 0.8%, 1.6%, and 31% among T2MI(2012reclassified) patients, respectively (all p < 0.01). Cardiovascular mortality at 90 days was 0% among T2MI(2012reclassified), which was similar to patients with noncardiac causes of chest discomfort (0.2%), and lower than T2MI(2007) (3.6%) and type 1 myocardial infarction (T1MI) (4.8%) (T2MI(2012reclassified) vs. T2MI(2007) and T1MI: p = 0.03 and 0.01, respectively). CONCLUSIONS T2MI(2012reclassified) has a substantially lower event-related mortality rate compared with T2MI(2007) and T1MI. (Advantageous Predictors of Acute Coronary Syndromes Evaluation [APACE] Study; NCT00470587) (C) 2017 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据